Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase of Trial: Phase I
Latest Information Update: 09 May 2016
At a glance
- Drugs TG 02 (Primary) ; Carfilzomib; Dexamethasone
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Tragara Pharmaceuticals
- 05 May 2016 Status changed from recruiting to completed.
- 12 Nov 2015 According to a Tragara Pharmaceuticals media release, clinical proof-of-concept has been achieved in this study,
- 05 Nov 2015 Planned End Date changed from 1 May 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov record.